The burden of white matter hyperintensities is a predictor of progressive mild cognitive impairment in patients with Parkinson's disease

European Journal of Neurology

Volumn 21, Issue 6, 2014, Pages

  Sunwoo, M K ^a   Jeon, S ^b   Ham, J H ^a   Hong, J Y ^c   Lee, J E ^a   Lee, J M ^b   Sohn, Y H ^a   Lee, P H ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Hanyang University   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Dementia converters; Parkinson's disease; White matter hyperintensities

Indexed keywords

AGED; ARTICLE; CHOLINERGIC PATHWAY HYPERINTENSITIES SCALE; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARKINSON DISEASE; PRIORITY JOURNAL; STROOP TEST; WHITE MATTER; COMPLICATION; DISEASE COURSE; LONGITUDINAL STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COGNITION; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; WHITE MATTER;

EID: 84899911663     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12412     Document Type: Article

References (40)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
2. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol 2010; 20: 633-639.
3. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
4. Copeland BJ, Schiess MC. Can mild cognitive impairment in Parkinson disease predict the development of dementia? JAMA Neurol 2013; 70: 553-555.
5. Hanganu A, Bedetti C, Jubault T, et al. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord 2013; 28: 1360-1369.
6. Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013; 81: 346-352.
7. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-1213.
8. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798.
9. Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2014; 85: 7-16.
10. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002; 17: 1221-1226.
11. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-183.
12. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848-855.
13. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet 2000; 356: 628-634.
14. Prasad K, Wiryasaputra L, Ng A, Kandiah N. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort. Dement Geriatr Cogn Disord 2011; 31: 431-434.
15. Dalaker TO, Larsen JP, Dwyer MG, et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage 2009; 47: 2083-2089.
16. Shin J, Choi S, Lee JE, Lee HS, Sohn YH, Lee PH. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. J Neurol Neurosurg Psychiatry 2012; 83: 315-321.
17. Kandiah N, Mak E, Ng A, et al. Cerebral white matter hyperintensity in Parkinson's disease: a major risk factor for mild cognitive impairment. Parkinsonism Relat Disord 2013; 19: 680-683.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
19. Kang Y, Na DL. Seoul Neuropsychological Screening Battery. Incheon: Human Brain Research & Consulting Co., 2003.
20. Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011; 26: 289-296.
21. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-356.
22. Goldman JG, Weis H, Stebbins G, Bernard B, Goetz CG. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord 2012; 27: 1129-1136.
23. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707; quiz 1837.
24. Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 2013; 84: 122-129.
25. Jeon S, Yoon U, Park JS, et al. Fully automated pipeline for quantification and localization of white matter hyperintensity in brain magnetic resonance image. Int J Imaging Syst Technol 2011; 21: 193-200.
26. Bocti C, Swartz RH, Gao FQ, Sahlas DJ, Behl P, Black SE. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke 2005; 36: 2126-2131.
27. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013; 70: 580-586.
28. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-1349.
29. Slawek J, Wieczorek D, Derejko M, et al. The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neurochir Pol 2008; 42: 505-512.
30. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-760.
31. Lee PH, Hwang EM, Hong HS, Boo JH, Mook-Jung I, Huh K. Effect of ischemic neuronal insults on amyloid precursor protein processing. Neurochem Res 2006; 31: 821-827.
32. Ha SY, Youn YC, Kim S, et al. A voxel-based morphometric study of cortical gray matter volume changes in Alzheimer's disease with white matter hyperintensities. J Clin Neurosci 2012; 19: 1506-1510.
33. Seo SW, Lee JM, Im K, et al. Cortical thinning related to periventricular and deep white matter hyperintensities. Neurobiol Aging 2012; 33: 1156-1167.
34. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-989.
35. Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, et al. Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab 2011; 31: 913-923.
36. Hattori T, Orimo S, Aoki S, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012; 33: 727-739.
37. Wang HC, Hsu JL, Leemans A. Diffusion tensor imaging of vascular parkinsonism: structural changes in cerebral white matter and the association with clinical severity. Arch Neurol 2012; 69: 1340-1348.
38. Shim YS, Youn YC, Na DL, et al. Effects of medial temporal atrophy and white matter hyperintensities on the cognitive functions in patients with Alzheimer's disease. Eur Neurol 2011; 66: 75-82.
39. Seo SW, Ahn J, Yoon U, et al. Cortical thinning in vascular mild cognitive impairment and vascular dementia of subcortical type. J Neuroimaging 2010; 20: 37-45.
40. Biesbroek JM, Kuijf HJ, van der Graaf Y, et al. Association between subcortical vascular lesion location and cognition: a voxel-based and tract-based lesion-symptom mapping study. The SMART-MR study. PLoS One 2013; 8: e60541.